15 January 2006 in Cancer Research
Nuclear factor-κB (NF-κB), a survival signal induced by tumor necrosis factor (TNF), contributes substantially to the resistance to TNF-induced cell death. Previous studies suggest that heat shock protein 90 (Hsp90) regulates the stability and function of receptor-interaction proteins (RIP) and IκB kinase β (IKKβ), the key components of the TNF-induced NF-κB activation pathway. In this study, we showed that the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG) was synergistic with TNF to induce apoptotic cell death in a panel of lung tumor-derived cell lines. Treatment with 17AAG caused degradation of RIP and IKKβ that, in turn, blocked TNF-induced NF-κB activation and antiapoptotic gene expression. The synergistic cytotoxicity was detected only when TNF treatment followed 17AAG preexposure. Importantly, the potentiation of cell death was abolished in NF-κB-disabled cells that express a nondegradable IκBα mutant (IκBαAA). These results suggest that the cytotoxicity seen with 17AAG and TNF treatment results from blocking TNF-induced NF-κB activation. The other components of the TNF receptor I signaling cascade were not altered, whereas TNF-induced c-Jun NH2-terminal kinase activation and apoptosis were potentiated. A similar synergism for inducing apoptosis was also observed in 17AAG-treated and TNF-related apoptosis-inducing ligand (TRAIL)–treated cancer cells. Our results suggest that NF-κB plays a key role in the resistance of lung cancer cells to TNF and TRAIL and that disabling this survival signal with 17AAG followed by TNF or TRAIL treatment could be an effective new therapeutic strategy for lung cancer. (Cancer Res 2006; 66(2): 1089-95)
1 April 2020 in Dose-Response
US homeland security concerns regarding the potential misuse of some radiation sources used in radiobiological research, for example, cesium-137 (137Cs), have resulted in recommendations by the National Research Council to conduct studies into replacing these sources with suitable X-ray instruments. The objective of this research is to compare the effectiveness of an X-RAD 320 irradiator (PXINC 2010) with a 137Cs irradiator (Gammacell-1000 Unit) using an established bone marrow chimeric model. Using measured radiation doses for each instrument, we characterized the dose–response relationships for bone marrow and splenocyte ablation, using a cytotoxicity-hazard model. Our results show that the X-RAD 320 photon energy spectrum was suitable for ablating bone marrow at the 3 exposure levels used, similar to that of 137Cs photons. However, the 320-kV X-rays were not as effective as the much higher energy γ rays at depleting mouse splenocytes. Furthermore, the 3 X-ray levels used were less effective than the higher energy γ rays in allowing the successful engraftment of donor bone marrow, potentially as a result of the incomplete depletion of the spleen cells. More defined studies are warranted for determining whether bone marrow transplantation in mice can be successfully achieved using 320-kV X-rays. A higher X-ray dose then used is likely needed for transplantation success.
15 April 2012 in Cancer Research
BSBalasubramanian Srinivasan
Balasubramanian Srinivasan
+3
Chalcone-based compounds are potential agents for cancer chemoprevention and chemotherapy. The recently developed chalcone-based compound SBC2 suppresses xenograft tumor growth in nude mice, however, the mechanisms by which SBC2 kills cancer cells are elusive. In this study, we have investigated the cellular signaling pathways involved in SBC2's cytotoxicity in cancer cells derived from lung and bladder tumors. SBC2 potently killed different cancer cells, which was effectively blocked by the necroptosis inhibitor Necrostatin-1 and knockdown of the necroptosis pathway components RIP1 and RIP3, suggesting that SBC2-induced cytotoxicity is associated with necroptosis. SBC2 robustly activated JNK and ERK through activation of their upstream activating kinases MEKK1 and MKK7. Blocking JNK and ERK effectively blocked SBC2-induced cytotoxicity, implying an important role of these MAPKs in SBC2-induced cancer cell death. In addition, SBC2 strongly induced autophagy, which was suppressed when JNK was blocked. Furthermore, SBC2 triggered BCL-XL phosphorylation that was dependent on JNK. Importantly, suppression of autophagy with either pharmacological inhibitors or a siRNA targeting the essential autophagy component ATG7 effectively attenuated SBC2-induced cell death. These results suggest that SBC2 kills cancer cells through activating JNK-mediated and autophagy-associated necroptosis. Taken together, our observations substantiate SBC2 as a potential anticancer therapeutic and identify a novel pathway for cancer cell killing by SBC2 that involves autophagy and necroptosis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2277. doi:1538-7445.AM2012-2277